JSLL Jeena Sikho Q1 FY26 results (Apr–Jun 2025) and concall
Jeena Sikho reported a strong Q1 FY26, driven by robust growth in both services and products, particularly private Panchakarma. The company is aggressively expanding its OTC product portfolio and bed capacity, leveraging partnerships with Ayurvedic colleges. Management expressed high confidence in achieving ambitious growth and margin targets, while also focusing on technology integration and patient-centric care.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 114 | 116 | 139 | 174 |
| EBITDA | 40 | 30 | 46 | 79 |
| Net profit | 27 | 13 | 25 | 51 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
